#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Erythema multiforme Haemolytic uraemic syndrome Familial haemophagocytic lymphohistiocytosis Waldenstrom's macroglobulinaemia refractory Heritable pulmonary arterial hypertension Blood iron increased Extra-osseous Ewing's sarcoma Hepatoblastoma Neoplasm malignant Fallopian tube cancer Cardiac sarcoidosis Aicardi-Goutieres syndrome Adenomatous polyposis coli Sjogren's syndrome Neurodegenerative disorder More trials…

    Learn about Rare Diseases

    Hereditary motor and sensory neuropathy – Trials in Disease Pleomorphic leiomyosarcoma – Basic Information Lennox-Gastaut syndrome – Diagnostics Acquired haemophilia Prolymphocytic leukaemia – Basic Information Usher’s syndrome Nephroblastoma – Treatment Nephrotic syndrome Cerebral arteriovenous malformation haemorrhagic Leukoencephalopathy – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cloxacillin Purified Egg Phospholipids Glepaglutide Bosutinib Oritavancin SULBACTAM SODIUM Metformin Embonate Tildrakizumab GLYCYL-TYROSINE Imlifidase Lamivudine GS-1720 Gen1046 Tislelizumab Dcc-3116 Xanthum Gum Nepafenac Alxn1850 Aluminium Oxide, Hydrated BLEXIMENIB More therapies…

    Learn about Your Condition

    Deafness traumatic Peripheral artery stenosis Tetanus Thalassaemia beta Fabry's disease Hypochromic anaemia Endometrial cancer metastatic Pneumonia Brain injury Bartonellosis Behcet's syndrome Thymoma Acquired ATTR amyloidosis Lupus nephritis Progressive multiple sclerosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur.
    • Ixazomib Citrate
    • Isatuximab
    Germany

  • Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    • Carfilzomib
    • Dexamethasone
    Belgium Czechia Germany Greece Italy The Netherlands +2

  • Study on the Effectiveness and Safety of Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    • Bortezomib
    • Dexamethasone
    Denmark Ireland

  • Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Elranatamab
    Belgium France Germany Poland Spain

  • Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Elranatamab
    Austria Belgium Czechia Finland France Germany +7

  • Study of Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone for Treating Multiple Myeloma Patients with Extramedullary Disease

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Cyclophosphamide
    • Daratumumab
    Greece Italy
Previous Page
1 … 13 14 15 16 17 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!